Gupta Bhavna, Ahluwalia Pallavi, Gupta Nidhi, Gupta Anish
Department of Anaesthesia, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Department of Anaesthesia, Teerthanker Mahaveer Medical College, Moradabad, Uttar Pradesh, India.
Indian J Crit Care Med. 2023 Aug;27(8):572-579. doi: 10.5005/jp-journals-10071-24511.
Coronavirus disease-2019 (COVID-19) is an extremely contagious illness caused by the SARS-CoV-2 virus and has been declared a pandemic by the World Health Organization (WHO). There are currently no particular treatments, however, nebulized heparin has been offered as a viable therapy. The purpose of this systematic review is to assess the efficacy of nebulized heparin in COVID-19 patients with respiratory symptoms.
Relevant studies were identified through a systematic search of the PubMed, Medline, Embase, Cochrane Library and Web of Science, and Scopus databases. The search terms included "nebulized heparin," "COVID-19," and "SARS-CoV-2." Studies that evaluated the use of nebulized heparin in COVID-19 patients with respiratory symptoms were included. The rest of the studies along with those that were not published in English were excluded. The systematic review was registered under PROSPERO-CRD42023413927.
Five studies have been included in this systematic review. Case reports, case series, observational studies, and randomized controlled trial (RCT) comprised the studies. The patient sample sizes ranged from 2 to 98. The studies assessed the efficacy of nebulized heparin in COVID-19 patients with variable disease severity. The evaluated outcomes included mortality, hospital stay duration, oxygen requirements, and laboratory parameters.
Based on the clinical studies included in this systematic review, nebulized heparin may be useful in the management of COVID-19. Oxygen saturation was greater, inflammatory indicators were lower, and hospital stays were shorter in these patients. However, the studies had limitations, including inconsistent sample sizes, varying dosages of nebulized heparin, and no control groups. Nebulized heparin in patients with COVID-19 needs to be studied further to determine its safety and effectiveness.
Gupta B, Ahluwalia P, Gupta N, Gupta A. Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review. Indian J Crit Care Med 2023;27(8):572-579.
2019冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的一种极具传染性的疾病，世界卫生组织（WHO）已宣布其为大流行病。目前尚无特效治疗方法，不过，雾化吸入肝素已被视为一种可行的治疗手段。本系统评价的目的是评估雾化吸入肝素对有呼吸道症状的COVID-19患者的疗效。
通过系统检索PubMed、Medline、Embase、Cochrane图书馆、科学网和Scopus数据库来确定相关研究。检索词包括“雾化吸入肝素”“COVID-19”和“SARS-CoV-2”。纳入评估雾化吸入肝素在有呼吸道症状的COVID-19患者中应用的研究。排除其他研究以及非英文发表的研究。该系统评价已在PROSPERO-CRD42023413927注册。
本系统评价纳入了5项研究。这些研究包括病例报告、病例系列、观察性研究和随机对照试验（RCT）。患者样本量从2到98不等。这些研究评估了雾化吸入肝素对不同疾病严重程度的COVID-19患者的疗效。评估的结局指标包括死亡率、住院时间、氧气需求和实验室参数。
基于本系统评价纳入的临床研究，雾化吸入肝素可能对COVID-19的治疗有用。这些患者的血氧饱和度更高，炎症指标更低，住院时间更短。然而，这些研究存在局限性，包括样本量不一致、雾化吸入肝素剂量不同以及没有对照组。COVID-19患者使用雾化吸入肝素需要进一步研究以确定其安全性和有效性。
Gupta B, Ahluwalia P, Gupta N, Gupta A. 雾化吸入肝素在有呼吸道症状的COVID-19患者临床结局中的作用：一项系统评价。《印度重症监护医学杂志》2023；27(8):572 - 579。
